Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095

British Journal of Pharmacology

Volumn 132, Issue 2, 2001, Pages 578-586

  Arakawa, Kenji ^a   Ishihara, Tomomi ^a   Oku, Akira ^a   Nawano, Masao ^a   Ueta, Kiichiro ^a   Kitamura, Kazuyuki ^a   Matsumoto, Mamoru ^a   Saito, Akira ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Antidiabetic agents; db db mice; Diabetes; Nephropathy; T 1095

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 3 (BENZO[B]FURAN 5 YL) 2',6' DIHYDROXY 4' METHYLPROPIOPHENONE 2' O (6 O METHOXYCARBONYL BETA DEXTRO GLYCOPYRANOSIDE); GLUCOPYRANOSIDE; GLUCOSE TRANSPORTER; PHLORIZIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; INSULIN RELEASE; MESANGIUM CELL; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 0035122471     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703829     Document Type: Article

References (38)

1. Development of the insulin secretory defect in genetically diabetic (db/db) mouse
2. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: Evidence for reversal following phlorizin treatment
3. Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin
4. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
5. Renal handling of D-glucose and other sugars
6. Pathogenesis of NIDDM. A balanced overview
7. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice
8. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4)
9. Glucose transporters of the glomerulus and the implications for diabetic nephropathy
10. Laboratory animals exhibiting obesity and diabetes syndromes
11. +-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety
12. +-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4′-dehydroxyphlorizin derivatives
13. Diabetes, a new mutation in the mouse
14. Evidence that increased glucose cycling in islets of diabetic ob/ob mice is a primary feature of the disease
15. Hyperglycemia and microvascular and macrovascular disease in diabetes
16. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats
17. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse
18. Prevention of diabetic nephropathy by diet control in the db/db mouse
19. Phlorizin hydrolase: A β-glucosidase of hamster intestinal brush border membrane
20. A rapid method for the isolation of kidney brush border membranes
21. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria?
22. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats
23. Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver
24. +-glucose cotransporters, may provide a novel approach to treating diabetes
25. +-glucose cotransporter, in neonatally streptozotocin-treated rats
26. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice
27. Diabetes complications: Why is glucose potentially toxic?
28. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations
29. Glucose toxicity: The implications of hyperglycemia in the pathophysiology of diabetes mellitus
30. Glucose toxicity
31. Structure and function of hexose transporters
32. Glucose transport in the renal proximal tubule
33. Long-term effects of aminoguanidine on insulin release and biosynthesis: Evidence that the formation of advanced glycosylation end products inhibits B cell function
34. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?
35. +-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept
36. +-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives substituted on the B ring
37. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
38. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: Implications for the management of diabetes